相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Valerie Janelle et al.
FRONTIERS IN IMMUNOLOGY (2020)
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Ugur Sahin et al.
NATURE (2020)
Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses
Yusuf Dolen et al.
ONCOIMMUNOLOGY (2020)
Cross-talk between iNKT cells and CD8 T cells in the spleen requires the IL-4/CCL17 axis for the generation of short-lived effector cells
M. Valente et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Therapeutic efficacy of nanoparticles and routes of administration
Dhrisya Chenthamara et al.
BIOMATERIALS RESEARCH (2019)
Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8(+) T Cell Activation
Liping Qiu et al.
SMALL (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy
Jianbo Jia et al.
FRONTIERS IN ONCOLOGY (2018)
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Olivier Gasser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4(+) T Cells after Intercellular Antigen Transfer
Jean Francois Fonteneau et al.
JOURNAL OF IMMUNOLOGY (2016)
Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses
Yusuf Dolen et al.
ONCOIMMUNOLOGY (2016)
Non-glycosidic compounds can stimulate both human and mouse iNKT cells
John-Paul Jukes et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
P. Baumgaertner et al.
ONCOIMMUNOLOGY (2016)
New York esophageal squamous cell carcinoma-1 and cancer immunotherapy
Ali Esfandiary et al.
IMMUNOTHERAPY (2015)
Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays
Nicole Bidmon et al.
JOURNAL OF IMMUNOLOGY (2015)
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine
Todd Bartkowiak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus
Ji-Li Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Cytokine-dependent regulation of dendritic cell differentiation in the splenic microenvironment
Theresa Globisch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
iNKT-cell help to B cells: A cooperative job between innate and adaptive immune responses
Paolo Dellabona et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Vaccination With NY- ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY- ESO-1 Antigen
Hisashi Wada et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes
Petra Simon et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Kunle Odunsi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
Shinichi Kageyama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions
Patrick J. Brennan et al.
NATURE REVIEWS IMMUNOLOGY (2013)
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
Kazuhiro Kakimi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery
Neil C. Robson et al.
BLOOD (2010)
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy
Stacey N. Akers et al.
FUTURE ONCOLOGY (2010)
NKT-cell help to B lymphocytes can occur independently of cognate interaction
Elena Tonti et al.
BLOOD (2009)
Harnessing invariant NKT cells in vaccination strategies
Vincenzo Cerundolo et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation
Martijn S. Bijker et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Naomi N. Hunder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8(+) and CD4(+) T-cell responses
Luciene Lopes et al.
JOURNAL OF VIROLOGY (2008)
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1
Heather Jackson et al.
JOURNAL OF IMMUNOLOGY (2006)
Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes
H Benlalam et al.
JOURNAL OF IMMUNOLOGY (2003)
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells
IF Hermans et al.
JOURNAL OF IMMUNOLOGY (2003)
Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
S Fujii et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The use of chimeric A2Kb tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice
EM Choi et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
S Gnjatic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
